Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects-Reference-Cited by-同舟云学术

Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects

Published:2022-05-25 Issue:10 Volume:88 Page:4573-4584
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Sharma Shringi¹^ORCID,Pepin Xavier²,Cheung Jean³,Zheng Lianqing⁴,Wei Hua⁵,Townsley Danielle⁶,Han David⁷,Majewski Michal⁸,Ware Joseph A.⁵,Mann James⁹,Munugalavadla Veerendra¹⁰,Sheridan Louise¹¹,Patel Priti¹²,Gupta Ashok⁶,Tomkinson Helen¹³

Affiliation:

1. Quantitative Clinical Pharmacology AstraZeneca South San Francisco CA USA

2. New Modalities & Parenteral Development, Pharmaceutical Technology & Development, Operations AstraZeneca Macclesfield UK

3. Hematology, Research and Development AstraZeneca South San Francisco CA USA

4. Late Hematology Statistics, Oncology Biometrics AstraZeneca South San Francisco CA USA

5. Acerta Pharma (a member of the AstraZeneca Group) South San Francisco CA USA

6. Oncology Research and Development AstraZeneca Gaithersburg MD USA

7. Parexel International Early Phase Clinical Unit (Los Angeles) Glendale CA USA

8. Oncology Research and Development, Clinical Operations, AstraZeneca Toronto Canada

9. Oral Product Development, Pharmaceutical Technology & Development, Operations AstraZeneca Macclesfield UK

10. Translational Medicine, Hematology, Research and Early Development AstraZeneca South San Francisco CA USA

11. Product Leadership, Pharmaceutical Technology & Development, Operations AstraZeneca Macclesfield UK

12. Clinical Development Hematology, Oncology Research and Development AstraZeneca South San Francisco CA USA

13. Clinical Pharmacology & Quantitative Pharmacology (CPQP), Clinical Pharmacology and Safety Sciences, Research and Development AstraZeneca Cambridge UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15362

Reference29 articles.

1. Calquence (acalabrutinib) [Full Prescribing Information]. U.S. Food and Drug Administration website. In Wilmington DE: AstraZeneca Pharmaceuticals LP 2019.

2. Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation

3. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors

4. A review of rabeprazole in the treatment of acid‐related diseases;Pace F;Ther Clin Risk Manag,2007

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration;Cancer Treatment Reviews;2024-09

2. Alternatives for the administration of oral antineoplastics in patients with swallowing difficulties;Journal of Chemotherapy;2024-05-20

3. Proton pump inhibitors: Weighing the benefits and risks across various health conditions;British Journal of Clinical Pharmacology;2023-11-27